Brain vulnerability to chemotherapy toxicities

Psycho-Oncology

Volumn 21, Issue 11, 2012, Pages 1141-1148

  Ahles, Tim A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

brain vulnerability; cancer; chemotherapy; cognition; oncology

Indexed keywords

APOLIPOPROTEIN E; CATECHOL METHYLTRANSFERASE; DOPAMINE; EXEMESTANE; FLUOXETINE; TAMOXIFEN;

AGING; BREAST CANCER; CLINICAL FEATURE; COGNITION; DEMENTIA; FRONTAL CORTEX; GENETICS; HEREDITY; HUMAN; NEUROPSYCHOLOGY; NONHUMAN; PROSTATE CANCER; REVIEW; RISK FACTOR; SIDE EFFECT;

BRAIN VULNERABILITY; CANCER; CHEMOTHERAPY; COGNITION; ONCOLOGY;

ANTINEOPLASTIC AGENTS; BRAIN; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COGNITION; COGNITION DISORDERS; FEMALE; HUMANS; MODELS, BIOLOGICAL; NEUROPSYCHOLOGICAL TESTS; SURVIVORS;

EID: 84868519144     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.3196     Document Type: Review

References (75)

1. Oxman TE, Silberfarb PM,. Serial cognitive testing in cancer patients receiving chemotherapy. Am J Psychiatry 1980; 137: 1263-1265.
2. Tannock IF, Ahles TA, Ganz PA, van Dam FS,. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004; 22: 2233-2239.
3. Vardy J, Wefel JS, Ahles TA, Tannock IF, Schagen SB,. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice Cognitive Workshop. Ann Oncol 2008; 19: 623-629.
4. Wefel JS, Vardy J, Ahles TA, Schagen S,. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in cancer patients. Lancet Oncol 2011; 12: 703-708.
5. Wefel JS, Lenzi R, Theriault RL,. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal study. Cancer 2004; 100: 2292-2299.
6. Mar Fan HG, Houede-Tchen N, Yi QL, et al,. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective study. J Clin Oncol 2005; 23: 8025-8032.
7. Schilling V, Jenkins V, Morris R, Deutsch G, Bloomfield D,. The effects of adjuvant chemotherapy on cognition in women with breast cancer-preliminary results of an observational study. Breast 2005; 14: 142-150.
8. Bender CM, Sereika SM, Berga SL, et al,. Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology 2006; 15: 422-430.
9. Hurria A, Rosen C, Hudis C, et al,. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc 2006; 54: 925-931.
10. Jenkins V, Shilling V, Deutsch G, et al,. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 2006; 94: 828-834.
11. Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ, van Dam FS,. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 2006; 98: 1742-1745.
12. Hermelink K, Untch M, Lux MP, et al,. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 2007; 109: 1905-1913.
13. Stewart A, Collins B, Mackenzie J, Tomiak E, Verma S, Bielajew C,. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psycho-Oncology 2008; 17: 122-130.
14. Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S,. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psycho-Oncology 2009; 18: 134-143.
15. Hermelink K, Henschel V, Untch M, Bauerfeind I, Lux MP, Munzel K,. Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study. Cancer 2008; 113: 2431-2439.
16. Mehlsen M, Pedersen AD, Jensen AB, Zachariae R,. No indications of cognitive side effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. Psycho-Oncology 2009; 18: 248-257.
17. Quesnel C, Savard J, Ivers H,. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat 2009; 116: 113-123.
18. Vearncombe KJ, Rolfe M, Wright M, Pachana NA, Andrew B, Beadle G,. Predictors of cognitive decline after chemotherapy in breast cancer patients. J Int Neuropsychol Soc 2009; 15: 951-962.
19. Ahles TA, Saykin AJ, McDonald BC, et al,. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: the impact of age and cognitive reserve. J Clin Oncol 2010; 28: 4434-4440.
20. Debess J, Riis JO, Engebjerg MC, Ewertz M,. Cognitive function after adjuvant treatment from early breast cancer: a population-based longitudinal study. Breast Cancer Res Treat 2010; 121: 91-100.
21. Tager FA, McKinley PS, Schnabel FR, et al,. The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study. Breast Cancer Res Treat 2010; 123: 25-34.
22. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA,. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 2010; 116: 3348-3356.
23. Hedayati E, Alinaghizadeh H, Schedin A, Nyman H, Albertsson M,. Effects of adjuvant treatment on cognitive function in women with early breast cancer. Eur J Oncol Nurs 2012; 16: 315-322.
24. Jansen CE, Cooper BA, Dodd MJ, Miaskowski CA,. A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer 2010; 19: 1647-1656.
25. Biglia N, Bounous VE, Malabaila A, et al,. Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. Eur J Cancer 2012; 21: 485-492.
26. Ahles TA, Root JC, Ryan EL,. Cancer and cancer treatment associated cognitive change: an update on the state of the science. J Clin Oncol, in press.
27. Ahles TA, Saykin AJ, McDonald BC, et al,. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat 2008; 110: 143-152.
28. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA,. Chemo brain in breast carcinoma? A prologue. Cancer 2004; 101: 466-475.
29. Ahles TA, Saykin AJ,. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007; 7: 192-201.
30. Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA,. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 2004; 26: 955-969.
31. Schilder C, Seynaeve C, Beex LV, et al,. Effects of tamoxifen and exemestane on cognitive function of postmenopausal patients with breast cancer: results from the neuropsychological side study of the Tamoxifen and Exemestane Adjuvant Multinational Trial. J Clin Oncol 2010; 28: 1294-1300.
32. Hurria A, Somlo G, Ahles T,. Renaming "chemo brain". Cancer Invest 2007; 25: 373-377.
33. Harris SE, Deary IJ,. The genetics of cognitive ability and cognitive ageing in healthy older people. Trends Cogn Sci 2011; 15: 388-394.
34. Ahles TA, Saykin AJ, Noll WW, et al,. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psycho-Oncology 2003; 12: 612-619.
35. Small BJ, Sharp Rowson K, Walsh E, et al,. Catechol-o-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Cancer 2011; 117: 1369-1376.
36. Inagaki M, Yoshikawa E, Matsuoka Y, et al,. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 2007; 109: 146-156.
37. Abraham J, Haut MW, Moran MT, Filburn S, Lemiuex S, Kuwabara H,. Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clin Breast Cancer 2008; 8: 88-91.
38. Kopplemans V, de Ruiter MB, van der Lijn F, et al,. Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy. Breast Cancer Res Treat 2012; 132: 1099-1106.
39. Deprez S, Amant F, Yigit R, et al,. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired functioning in breast cancer patients. Hum Brain Mapp 2011; 32: 480-493.
40. de Ruiter MB, Reneman L, Boogerd W, et al,. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp, e-pub ahead of print.
41. Yoshikawa E, Matsuoka Y, Inagaki M, et al,. No adverse effects of adjuvant chemotherapy on hippocampal volume in Japanese breast cancer survivors. Breast Cancer Res Treat 2005; 92: 81-84.
42. McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ,. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat 2010; 123: 819-828.
43. Deprez S, Amant F, Smeets A, et al,. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol 2012; 30: 274-281.
44. Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA,. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol 2007; 25: 3866-3870.
45. Kesler SR, Kent JS, O'Hara R,. Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol 2011; 68: 1447-1453.
46. Kesler SR, Bennett FC, Mahaffey ML, Spiegel D,. Regional brain activation during verbal declarative memory in metastatic breast cancer. Clin Cancer Res 2009; 15: 6665-6673.
47. de Ruiter MD, Reneman L, Boogerd W, et al,. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp 2011; 38: 1206-1219.
48. Silverman DH, Dy CJ, Castellon SA, et al,. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 2007; 103: 303-311.
49. McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ,. Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional MRI study. J Clin Oncol 2012; 30: 2500-2508.
50. Cimprich B, Reuter-Lorenz P, Nelson J, et al,. Prechemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol 2010; 32: 324-331.
51. Scherling C, Collins B, MacKenzie J, Bielajew C, Smith A,. Pre-chemotherapy differences in visuospatial working memory in breast cancer patients compared to controls: an fMRI study. Front Hum Neurosci 2011; 5: 1-21.
52. Seigers R, Fardell JE,. Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research. Neurosci Biobehav Rev 2011; 35: 729-741.
53. Dietrich J, Han R, Yang Y, Mayer-Pröschel M, Noble M,. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 2006; 5: 1-23.
54. Lyons L, ElBeltagy M, Bennett G, Wigmore P,. Fluoxetine counteracts the cognitive and cellular effects of 5-fluorouracil in the rat hippocampus by a mechanism of prevention rather than recovery. PLoS One 2012; 1: e30010.
55. ElBeltagy M, Mustafa S, Umka J, et al,. Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil. Behav Brain Res 2010; 208: 112-117.
56. Irminger-Finger I,. Science of cancer and aging. J Clin Oncol 2007; 25: 1844-1851.
57. Campisi J, Yaswen P,. Aging and cancer cell biology, 2009. Aging Cell 2009; 8: 221-225.
58. Maccormick RE,. Possible acceleration of aging by adjuvant chemotherapy: a cause of early onset frailty. Med Hypothesis 2006; 67: 212-215.
59. Campisi J, d'Adda di Fagagna F,. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8: 729-740.
60. Brown K,. Is tamoxifen a genotoxic carcinogen in women? Mutagenesis 2009; 24: 391-404.
61. Gavrilov LA, Gavrilova NS,. Reliability theory of aging and longevity. In Handbook of the Biology of Aging (6th edn), Masoro EJ, Sustad ST, (eds). Academic Press: Burlington, MA, 2006.
62. Lindenberger U, Nagel IE, Chicherio C, Li SC, Heekeren HR, Bäckman L,. Age-related decline in brain resources modulates genetic effects on cognitive functioning. Frontiers in Neuroscience 2008; 2: 234-244.
63. Yamada TH, Denburg NL, Beglinger LJ, Schultz SK,. Neuropsychological outcomes of older breast cancer survivors: cognitive features ten or more years after chemotherapy. J Neuropsychiatry Clin Neurosci 2010; 22: 48-54.
64. Ahles TA, Saykin AJ, Furstenberg CT, et al,. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002; 20: 485-493.
65. Koppelmans V, Breteler MM, Boogerd W, Seynaeve C, Gundy C, Schagen SB,. Neuropsychological performance in breast cancer survivors more than 20 years after adjuvant chemotherapy. J Clin Oncol 2012; 30: 1080-1086.
66. Peelle JE, Cusack, R, Henson RN,. Adjusting for global effects in voxel-based morphometry: gray matter decline in normal aging. Neuroimage 2012; 60: 1503-1516.
67. Gunning-Dixon FM, Brickman AM, Cheng JC, Alexopoulos GS,. Aging of cerebral white matter: a review of MRI findings. Int J Geriatr Psychiatry 2009; 24: 109-117.
68. Heck JE, Albert SM, Franco R, Gorin SS,. Patterns of dementia diagnosis in surveillance, epidemiology, and end results breast cancer survivors who use chemotherapy. J Am Geriatr Soc 2008; 56: 1687-1692.
69. Baxter NN, Durham SB, Phillips KA, Habermann EB, Virning BA,. Risk of dementia in older breast cancer survivors: a population-based cohort study of the association with adjuvant chemotherapy. J Am Geriatr Soc 2009; 57: 403-411.
70. Raji MA, Tamborello LP, Kuo YF, et al,. Risk of subsequent dementia diagnoses does not vary by types of adjuvant chemotherapy in older women with breast cancer. Med Oncol 2009; 26: 452-459.
71. Heflin LH, Meyerowitz BE, Hall P, et al,. Cancer as a risk factor for long-term cognitive deficits and dementia. J Natl Cancer Institute 2005; 97: 854-856.
72. Kohli SS, Fisher G, Tra Y, et al,. The effect of modafinil on cognitive function in breast cancer survivors. Cancer 2009; 115: 2605-2616.
73. Lundorff LE, Jønsson BH, Sjøgren P,. Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial. Palliat Med 2009; 23: 731-738.
74. Ferguson JR, McDonald BC, Rocque MA, et al,. Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial. Psycho-Oncology 2012; 21: 176-186.
75. Plassman BL, Williams JW, Burke JR, Holsinger T, Benjamin S,. Systematic review: factors associated with risk for and possible prevention of cognitive decline in later life. Ann Intern Med 2010; 153: 182-193.